diethylphosphonoethyl acetate | 15300-97-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: diethylphosphonoethyl acetate
• 英文别名: 2-(diethoxyphosphoryl)ethyl acetate；2-Diethoxyphosphorylethyl acetate
• CAS: 15300-97-7
• 化学式: C₈H₁₇O₅P
• 分子量: 224.194
• InChiKey: TUJWGDXCTRWVDC-UHFFFAOYSA-N

物化性质

• 溶解度：
  溶于氯仿、二氯甲烷

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  diethylphosphonoethyl acetate 在 盐酸 作用下， 以 甲醇 为溶剂， 以88%的产率得到2-二乙氧基磷酰乙醇
  参考文献：
  名称：

  Synthesis and pharmacological activity of alkylphosphonic and oxy derivatives

  摘要：

  DOI：

  10.1007/bf00758440
• 作为产物：
  描述：

  乙酸乙烯酯 、 亚磷酸二乙酯 在 过氧化氢苯甲酰 作用下， 生成 diethylphosphonoethyl acetate
  参考文献：
  名称：

  Preparation and Properties of Diethyl Acetoxyalkylphosphonates

  摘要：

  DOI：

  10.1021/ja01565a054

文献信息

• Process for the preparation of phosphonic acid dihalides
  申请人：Hoechst Aktiengesellschaft

  公开号：US03972923A1

  公开（公告）日：1976-08-03

  Process for preparing phosphonic acid dihalides of the formula ##EQU1## wherein R is alkyl of 1 to 18 carbon atoms, cycloalkyl of 4 to 8 carbon atoms, alkenyl of 2 to 18 carbon atoms, phenyl, phenalkyl or alkyl-phenyl of 7 to 8 carbon atoms, phenyl, phenalkyl or alkyl-phenyl of 7 to 8 carbon atoms, all radicals R optionally being substituted by chlorine, bromine, cyano or lower acyloxy, and wherein X is halogen such as 2-chloroethane phosphonic acid dichloride, by reacting phosphonic or thio-phosphonic acids of the formula ##EQU2## wherein Y is oxygen or sulfur, their salts or functional derivatives, with acid halides of the formula (CO).sub.n X.sub.2 (III) wherein X is chlorine or bromine and n is 1 or 2, in the presence of 0.2 - 5% or in the presence of 0.01 to 0.2% by weight of 1. compounds containing at least one tri- to pentavalent nitrogen or phosphorus atom, which in the case of nitrogen is bound with 1 to 4, in the case of phosphorus with at least 3 valences to organic radicals having up to 20 carbon atoms, two of these valences optionally forming a double bond, or 2. mono-di- or tribasic organic or inorganic fully amidated acids or tri- or pentavalent phosphorus, the N atom of which optionally being substituted by aliphatic radicals having up to 20 carbon atoms, and the organic radicals of which contain up to 20 carbon atoms, If required, in the presence of an inert solvent.

  制备式为##EQU1##的膦酸二卤代物的过程，其中R是1至18个碳原子的烷基，4至8个碳原子的环烷基，2至18个碳原子的烯基，苯基，苯基烷基或7至8个碳原子的烷基苯基，苯基，苯基烷基或7至8个碳原子的烷基苯基，所有基团R可选择地被氯，溴，氰基或较低的酰氧基取代，其中X是卤素，例如2-氯乙烷膦酸二氯化物，通过将式为##EQU2##的膦酸或硫膦酸与式为(CO).sub.nX.sub.2(III)的酸卤反应而得，其中Y是氧或硫，它们的盐或功能衍生物，X是氯或溴，n为1或2，在0.2-5%的存在下或在0.01至0.2%的存在下按重量计的1.至少含有一个三至五价氮或磷原子的化合物，其中在氮的情况下与1至4个，在磷的情况下与至少3个价的有机基团结合，这些价中的两个可选择地形成双键，或2.单，二或三碱基的有机或无机全酰胺酸或三价或五价磷，其中N原子可选择地被含有最多20个碳原子的脂肪基团取代，其有机基团含有最多20个碳原子，如有必要，在惰性溶剂的存在下。
• Imidazolylamide derivative
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US10898469B2

  公开（公告）日：2021-01-26

  The present invention pertains to an imidazolylamide derivative represented by formula (1) that exhibits an exceptional suppressive effect on cancer cell sphere formation ability and that is useful as an antitumor agent that can be administered orally, or a pharmacologically acceptable salt thereof. [In the formula, ring Q1 represents a C6-10 aryl group or the like; m represents 0, 1, 2, 3, 4, or 5; R3, independently when multiple, represent(s) a halogen atom or the like; R1 and R2 independently represent a hydrogen atom or the like; W1 represents a C1-4 alkylene group (said group may be substituted by 1-3 fluorine atoms or C3-7 cycloalkyls); W2 represents —NR4aC(O)— or the like (where R4a represents a hydrogen atom or C1-6 alkyl group); and ring Q2 represents a C6-10 arylgroup or the like]

  该发明涉及一种由式（1）表示的咪唑酰胺衍生物，该衍生物对癌细胞球形成能力具有显著的抑制作用，并且可作为一种口服抗肿瘤剂或其药理学上可接受的盐。【在该式中，环Q1代表C6-10芳基或类似物；m代表0、1、2、3、4或5；R3，当多个时，独立地代表卤原子或类似物；R1和R2独立地代表氢原子或类似物；W1代表C1-4烷基（该基团可被1-3氟原子或C3-7环烷基取代）；W2代表—NR4aC(O)—或类似物（其中R4a代表氢原子或C1-6烷基）；环Q2代表C6-10芳基或类似物】
• SULFONAMIDE COMPOUNDS AND THE USE
  申请人：OGAWA Masami

  公开号：US20100022601A1

  公开（公告）日：2010-01-28

  The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and/or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promoting PTH secretion. In addition, the compounds are useful as an effective component of a medicament for the prophylaxis and/or treatment of bone disorders such as osteoporosis, bone fracture, hypoparathyroidism and the like.

  提供以下式(1)的磺酰胺化合物，可用作预防或治疗包括骨质疏松症等骨疾病的CaSR拮抗剂的有效成分。这些化合物具有促进PTH分泌的卓越活性。此外，这些化合物还用作预防或治疗骨质疏松症、骨折、低甲状旁腺功能等骨疾病药物的有效成分。
• PYRAZOLE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2128138A1

  公开（公告）日：2009-12-02

  The present invention aims to provide an agent for the prophylaxis or treatment of diabetes, which has a superior hypoglycemic action, and is associated with a fewer side effects such as body weight gain and the like. The present invention relates to an agent for the prophylaxis or treatment of diabetes comprising a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof.

  本发明旨在提供一种用于预防或治疗糖尿病的药物，具有优越的降血糖作用，并且与较少的副作用，如体重增加等相关。本发明涉及一种用于预防或治疗糖尿病的药物，包括由以下式表示的化合物：其中每个符号如描述中所定义，或其盐，或其前药。
• Functional selectivity in phosphonate ester dealkylation with bromotrimethylsilane
  作者：Charles E. McKenna、John Schmidhuser

  DOI：10.1039/c39790000739

  日期：——

  Bromotrimethylsilane is highly selective for P–O silyldealkylation of mixed carboxylate–phosphonate alkyl esters and can be used to prepare trimethylsilyl amido-, alkynyl-, and iodoalkyl-phosphonates in good yield, thus making the corresponding phosphonic acids readily available via hydrolysis with neutral H2O.

  溴代三甲基硅烷对混合的羧酸酯-膦酸酯烷基酯的P-O甲硅烷基脱烷基化反应具有高度选择性，可用于制备三甲基硅烷基酰胺基，炔基和碘代烷基膦酸酯，收率很高，因此使相应的膦酸易于通过中性H水解获得2 O.